Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

Business Wire2021-12-07

DURHAM, N.C., December 06, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2189895106?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KquUgpA_uMRgIfOJiO_q9w--~B/aD0xMTk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/FvwsdJ7mf_.zXYSEu5w47w--~B/aD0xMTk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a9bec4dd59b00569b2a3bec74e26306","is_english":true,"pubTime":"2021-12-07 05:49","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2189895106","market":"us","top_or_hot":-1,"title":"Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021","media":"Business Wire","content":"<div>\n<p>DURHAM, N.C., December 06, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR ...</p>\n\n<a href=\"https://finance.yahoo.com/news/precision-biosciences-host-virtual-webcast-214900921.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 05:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/precision-biosciences-host-virtual-webcast-214900921.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DURHAM, N.C., December 06, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR ...</p>\n\n<a href=\"https://finance.yahoo.com/news/precision-biosciences-host-virtual-webcast-214900921.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRU.SI","symbol_name":"CSOP iEdge SREIT ETF US$","start_time":0,"source_url":"https://finance.yahoo.com/news/precision-biosciences-host-virtual-webcast-214900921.html","article_id":"2189895106","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KquUgpA_uMRgIfOJiO_q9w--~B/aD0xMTk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/FvwsdJ7mf_.zXYSEu5w47w--~B/aD0xMTk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a9bec4dd59b00569b2a3bec74e26306"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2189895106","pubTimestamp":1638827340,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"DURHAM, N.C., December 06, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clin","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRU.SI":"CSOP iEdge SREIT ETF US$","BK4181":"酒店及度假村房地产投资信托","DTIL":"Precision Biosciences Inc","HST":"美国豪斯特酒店"},"translate_title":"精密生物科学公司将于2021年12月11日星期六主办虚拟网络广播和电话会议，审查临时阶段1/2 A PBCAR0191 CAR T数据，并提供CAR T程序更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00699":1,"HST":1,"DTIL":0.9,"SRU.SI":0.6},"content_text":"DURHAM, N.C., December 06, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, December 11, 2021 at 7:30 PM ET.\nPrecision previously announced that abstracts accepted by ASH are now available at www.hematology.org, and the following two abstracts will be presented during oral presentation sessions:\nOral Presentation: #626. Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-cell Malignancies (Abstract #302)Presenting Author: Bijal Shah, M.D., Moffitt Cancer CenterDate/Time/Location: Saturday, December 11, 2021 at 4:15 PM ET in the Georgia World Congress Center, B401-B402\nOral Presentation: #704. Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL (Abstract #650)Presenting Author: Nitin Jain, M.D., The University of Texas MD Anderson Cancer CenterDate/Time/Location: Monday, December 13, 2021 at 10:45 AM ET in the Georgia World Congress Center, Sidney Marcus Auditorium\nCompany-Hosted Webcast and Conference Call InformationPrecision will host a conference call and webcast on Saturday, December 11, 2021 at 7:30 PM ET to discuss interim data results for PBCAR0191 presented at the ASH annual meeting, as well as additional updates regarding its allogeneic CAR T pipeline. This event is not an official program of the ASH annual meeting. The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, respectively. The conference ID number for the call is 1178837. Participants may access the live webcast, and accompanying presentation materials, as well as the archived webcast on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations.\nAbout Precision BioSciences, Inc.Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple \"off-the-shelf\" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211206005827/en/\nContacts\nInvestor Contact: Alex KellyChief Financial OfficerAlex.Kelly@precisionbiosciences.com\nMedia Contact: Maurissa MessierSenior Director, Corporate CommunicationsMaurissa.Messier@precisionbiosciences.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2189895106"}